Posts by droussel

KH-001 delays para-chloroamphetamine-induced ejaculation in anaesthetized rat.

Pfeiffer T, Gericke N, Razanakolona M, Behr-Roussel D, Bracconi M, Giuliano F, Protzko R. JSM, 2026, 23 (4), qdag044

Premature ejaculation remains a frequent male sexual dysfunction with limited therapeutic options. A recently published study involving Pelvipharm evaluated KH-001, a novel treatment candidate, in a rat model of para-chloroamphetamine-induced ejaculation.

In this model, efficacy was assessed using objective functional endpoints, including latency to ejaculation, proportion of animals ejaculating, seminal vesicle pressure and bulbospongiosus muscle electromyographic activity.

Acute administration of KH-001 increased latency to ejaculation in a dose-dependent manner. The physiological readouts also provided insight into the components of the ejaculatory response affected by treatment.

This study illustrates the value of functional preclinical models in identifying pharmacological activity and supporting the early development of new therapeutic approaches for premature ejaculation.

Pelvipharm supports drug developers working in male sexual dysfunction through tailored efficacy studies, dose-response evaluation and complementary mechanistic or PK/PD investigations.

Pelvipharm and Vella Bioscience Inc present new findings on the Relaxant Effects of Cannabidiol on myometrium at the ISSWSH Meeting in Long Beach, USA, February 12 – 15, 2026.

Harin Padma-Nathan will present a digital poster (#161) during an unmoderated poster session to extend new findings on the Relaxant Effects of Cannabidiol on myometrium.

“CBDA and CBD Diminish Spontaneous Contractions of the Myometrium in vitro and Significantly Ameliorate Pain in Primary Dysmenorrhea”

Padma-Nathan, H; Frid, M; Wheeler, C; Behr-Roussel, D; O’Gorman, E; Uloko, M; Simon, J.

Please reach out if you want to discuss these results on the relaxant effect of cannabidiol on myometrium and potential applications for you.

Pelvipharm extends its warmest wishes to our valued clients, partners, and collaborators as we embark on this promising new year.

May this new year bring you health, happiness and continued success. We look forward to collaborating with you and embracing new opportunities to advance intimate health together.

With our sincerest regards, The Pelvipharm Team.

Pelvipharm and Otrera Medical Inc present new findings on the Relaxant Effects of Cannabidiol in Rats at the ISSWSH Meeting in Atlanta, USA, February 27 – March 2, 2025.

Harin Padma-Nathan will present a digital poster during the poster session entitled “Clinical Trials / Novel Drugs, Methods and Technologies / Basic Science” to present new findings on the Relaxant Effects of Cannabidiol in Rats.

“Relaxant Effects of Cannabidiol on Electrical Field Stimulation-induced Smooth Muscle Contractility of Vaginal Strips from Normal and Oophorectomized Rats”

Padma-Nathan, H; Frid, M; Gorny, D; Assaly, R; Behr-Roussel, D.

Please reach out if you want to discuss our results on the relaxant effect of cannabidiol in rats and potential applications for you.

As we step into 2025, the Pelvipharm SAS team extends its heartfelt gratitude to all our collaborators, partners, and clients. Thank you for making 2024 an exceptional year! Your trust and support have been the cornerstone of our achievements.

Looking forward, we are thrilled to continue this journey together. Building on last year’s successes, we aim even higher in 2025 with unwavering dedication to innovation and excellence. Let’s make this year remarkable!

Presentation at the Congress of the ICS 2024 (International Continence Society) in  Madrid, Spain, 23-25 October, 2024 reports new Viral Vector HSV1 Efficacy Studies in urology.

Julien Ratelade from EG427 presented the results of a project performed in collaboration with Pelvipharm: